Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 3Gynecologic 3Sarcoma 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 323Fallopian Tube Neoplasms 159Carcinoma, Ovarian Epithelial 114Endometrial Neoplasms 77Uterine Cervical Neoplasms 72Neoplasms 28Carcinoma, Non-Small-Cell Lung 24Breast Neoplasms 23Brenner Tumor 21Recurrence 19Testicular Neoplasms 17Peritoneal Neoplasms 17Stomach Neoplasms 14Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Urinary Bladder Neoplasms 10Testicular Germ Cell Tumor 10Sarcoma 10Pancreatic Neoplasms 10Lung Neoplasms 10Colorectal Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Parkinson Disease 4, Autosomal Dominant Lewy Body 9Teratoma 8Ovarian Germ Cell Cancer 8Neuroectodermal Tumors, Primitive, Peripheral 8Central Nervous System Neoplasms 8Uterine Neoplasms 7Small Cell Lung Carcinoma 7Melanoma 7

Interventions

pembrolizumab 6Nivolumab 3Cisplatin 3Carboplatin 3Paclitaxel 2Fluorouracil 2tucatinib 1pertuzumab 1milademetan 1lenvatinib 1cemiplimab 1Trastuzumab 1Tomography, X-Ray Computed 1Ritonavir 1Radiation 1Prednisone 1Prednisolone 1Positron-Emission Tomography 1Pemetrexed 1Oxaliplatin 1Magnetic Resonance Imaging 1Leucovorin 1Itraconazole 1Gemcitabine 1Fulvestrant 1Cetuximab 1Capecitabine 1Brachytherapy 1Bevacizumab 1AZD9833 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Carboplatin × Gynecologic × Clear all
NCT04956640 2026-05-29

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Eli Lilly and Company

Phase 1/2 Active not recruiting
540 enrolled
GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

AstraZeneca

Phase 2 Recruiting
454 enrolled
GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04644068 2026-02-19

PETRA

AstraZeneca

Phase 1/2 Active not recruiting
702 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡